ZyVersa Therapeutics, Inc.
ZVSA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.10 | 0.00 | 0.00 |
| FCF Yield | -12,364.33% | -4,668.40% | -90,734.18% | -106.45% |
| EV / EBITDA | -0.00 | -15.63 | -0.15 | 0.30 |
| Quality | ||||
| ROIC | 176,981.89% | -29,405.91% | -23,876.30% | -13.71% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.07 | 0.69 | 785.16 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 296,445.56% | 296,445.56% | 296,445.56% | 296,445.56% |
| Free Cash Flow Growth | 7.55% | 14.13% | -144,603.61% | 99.96% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.03 | 0.71 | 1.19 |
| Interest Coverage | -157.99 | -15,719.74 | -17,937.34 | -9.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -64,449.27 |